Breast Cancer
Conference Coverage
BOLERO-2: Everolimus Plus Exemestane Delays Breast Cancer Progression
Major Finding: According to updated results median progression-free survival was 7.4 months for combination therapy patients and 3.2 months for...
News
IOM Dissects Environmental Risk Factors for Breast Cancer
News
Zoledronic Acid's Breast Cancer Benefit Extends 7 Years
Major Finding: Treatment with zoledronic acid led to a 28% reduction in breast cancer recurrence risk and a 37% reduction in mortality risk over 7...
News
Breast Cancer Gene Profile Identifies Early vs. Late Recurrences
News
Brachytherapy Doubles Breast Loss Risk
Major Finding: Accelerated partial-breast brachytherapy had a twofold higher 5-year mastectomy rate than whole breast irradiation and...
News
Practice Changers Expected at San Antonio Breast Cancer Symposium
News
Pertuzumab Enhanced Response to Standard Therapy in HER2+ Breast Cancer
Major Finding: The rate of complete pathologic response within the breast was 46% for therapy with all three agents, compared with 29% for...